Update shared on11 Sep 2025
Fair value Decreased 33%Analysts have lowered Harvard Bioscience’s price target from $3.00 to $2.00 due to increased uncertainty around research funding, drug pricing pressures, tariff risks, and a generally more cautious sector outlook.
Analyst Commentary
- Uncertainty surrounding basic research funding potentially impacting sector performance.
- Ongoing concerns about drug pricing pressures negatively affecting the company's outlook.
- Tariff-related challenges adding to operational and margin risk.
- Sector environment expected to remain uncertain in the near term.
- Heightened risk profile leading to a more conservative price target.
What's in the News
- Company raised Q2 2025 revenue guidance to $20.4 million from prior $18–20 million outlook and reiterated gross margin expectations of 55%–57%.
- Provided Q3 2025 revenue guidance of $19–21 million.
- CEO James W. Green resigned, with Board member John Duke appointed as successor.
- Received Nasdaq notification of non-compliance due to audit committee vacancy; company intends to regain compliance by appointing a new independent Board member and will rely on the Nasdaq cure period.
Valuation Changes
Summary of Valuation Changes for Harvard Bioscience
- The Consensus Analyst Price Target has significantly fallen from $3.00 to $2.00.
- The Future P/E for Harvard Bioscience has significantly fallen from 14.71x to 9.88x.
- The Consensus Revenue Growth forecasts for Harvard Bioscience has significantly risen from 1.4% per annum to 1.7% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.